Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name “Mango” (think: “Man, Go!”).
Company profile
Ticker
MGRX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
MangoRx Mexico • MangoRx UK Limited, a company incorporated ...
IRS number
873841292
MGRX stock data
Latest filings (excl ownership)
S-1
IPO registration
23 Apr 24
8-K
Entry into a Material Definitive Agreement
11 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
DEF 14A
Definitive proxy
1 Mar 24
PRE 14A
Preliminary proxy
20 Feb 24
8-K
Other Events
25 Jan 24
8-K
Other Events
23 Jan 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
EFFECT
Notice of effectiveness
20 Dec 23
Latest ownership filings
4
Jacob D. Cohen
29 Dec 23
SC 13D/A
Cohen Jacob D.
29 Dec 23
4
EUGENE M JOHNSTON
4 Oct 23
4
Amanda Elizabeth Hammer
4 May 23
3
Amanda Elizabeth Hammer
4 May 23
SC 13D
Cohen Jacob D.
3 May 23
4
Jacob D. Cohen
2 May 23
3
Alex P. Hamilton
21 Mar 23
3
Jonathan Arango
20 Mar 23
3
EUGENE M JOHNSTON
20 Mar 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.24 mm | |||||
Cash burn (monthly) | 599.82 k | |||||
Cash used (since last report) | 4.11 mm | |||||
Cash remaining | -2.87 mm | |||||
Runway (months of cash) | -4.8 |
Institutional ownership, Q2 2023
35.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 5 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 173.67 mm |
Total shares | 8.37 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cohen Jacob D. | 8.28 mm | $7.22 mm |
Colonial River Wealth Management | 36.10 k | $66.06 mm |
Two Sigma Investments | 27.10 k | $49.60 mm |
Independent Advisor Alliance | 26.00 k | $47.58 mm |
Private Trust Co Na | 1.50 k | $2.75 mm |
UBS UBS Group AG - Registered Shares | 249.00 | $456.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Dec 23 | Cohen Jacob D. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.32 | 125,000 | 40.00 k | 1,250,000 |
3 Oct 23 | Eugene M Johnston | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 200,000 |
1 May 23 | Amanda Elizabeth Hammer | Common Stock | Grant | Acquire A | No | No | 0 | 75,000 | 0.00 | 75,000 |
1 May 23 | Amanda Elizabeth Hammer | Stock Option Common Stock | Grant | Acquire A | No | No | 1.1 | 150,000 | 165.00 k | 150,000 |
10 Apr 23 | Cohen Jacob D. | Common Stock | Buy | Acquire P | No | No | 1 | 275,000 | 275.00 k | 8,275,000 |
4 Apr 23 | Cohen Jacob D. | Common Stock | Gift | Acquire G | No | No | 0 | 8,000,000 | 0.00 | 8,000,000 |
4 Apr 23 | Cohen Jacob D. | Common Stock | Gift | Dispose G | Yes | No | 0 | 8,000,000 | 0.00 | 0 |
News
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement With Mexican Pharmaceutical Manufacturer For Initial Development And Production Of Its Mango Erectile Dysfunction Products
12 Apr 24
12 Consumer Staples Stocks Moving In Tuesday's After-Market Session
9 Apr 24
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
25 Mar 24
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
20 Mar 24
MangoRx Launches 'PRIME' By MangoRx, Powered By Kyzatrex FDA Approved Oral Testosterone Replacement Therapy Treatment
12 Mar 24
Press releases
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
12 Apr 24
MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITY
13 Feb 24
MANGORX TO OFFER THE BIG GAME'S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS
6 Feb 24
MangoRx Accepting Pre Orders for its "PRIME", by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product
5 Feb 24